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Abstract: Sickle cell disease (SCD) is a genetically inherited condition caused by a point 
mutation in the beta globin gene. This results in the production of the abnormal hemoglobin, 
sickle hemoglobin (HbS). Hydroxycarbamide, is an antimetabolite/cytotoxic which works by 
inhibiting ribonucleotide reductase, blocking the synthesis of DNA and arresting cells in the 
S phase. In sickle cell anemia, it promotes fetal hemoglobin (HbF) synthesis, improves red cell 
hydration, decreases neutrophil and platelet count, modifies red cell endothelial cell interactions 
and acts as a nitric oxide donor. Trials have shown the clinical benefit of hydroxycarbamide in 
a subpopulation of adult patients with SCD, with a 44% reduction in the median annual rate 
of painful crises, a decrease in the incidence of acute chest syndrome and an estimated 40% 
reduction in overall mortality over a 9-year observational period. Its use in pediatrics has also been 
well established; trials have shown it is well tolerated and does not impair growth or development. 
In addition it decreases the number and duration of hospital attendences. A number of emerging 
uses of hydroxycarbamide currently are being investigated, such as stroke prevention.
Keywords: sickle cell anemia, hydroxycarbamide, hydroxyurea, maximum tolerated dose, 
vaso-occlusive crisis
Introduction
Sickle cell disease (SCD) is a genetically inherited condition caused by a point mutation 
causing the substitution of valine for glutamic acid at position 6 in the beta globin gene. 
This results in the production of the abnormal hemoglobin, sickle hemoglobin (HbS). 
The clinical phenotype can be seen in patients with homozygous sickle cell disease 
(HbSS), but also in patients who are compound heterozygotes of HbS and another 
abnormal hemoglobin such as hemoglobin C, D, E or O-Arab or beta thalassemia. 
Sickle cell disease is now the most common genetic disorder in the UK, affecting 
over 1 in 2000 live births and up to 1 in 300 births in some urban areas, and there is 
a worldwide annual birthrate of over 200,000 of which more than 90% are in Africa.1 
HbS polymerizes at low oxygen levels, making the red cell initially more rigid, and 
eventually irreversibly sickled. These red cells are less deformable and this results in 
vaso-occlusion within the end organ capillaries, leading to pain and organ dysfunction. 
In addition, ongoing hemolysis has an important role in disease pathophysiology by 
causing nitric oxide (NO) deficiency and vascular instability.2 Red blood cell dehydra-
tion and red cell adhesion to the endothelium, with subsequent endothelium activation 
also contribute to the pathophysiology of this condition.3 Despite being a single gene 
disorder there is considerable heterogeneity in the clinical severity seen, and this is 
thought to be in part due to the role of other genetic factors, such as the co-inheritance Therapeutics and Clinical Risk Management 2009:5 746
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of alpha thalassemia, and the presence of several single 
nucleotide polymorphisms (SNPs).4
Despite being one of the first inherited diseases character-
ized, treatment for SCD in the UK has lagged behind that in 
many other conditions. Hydroxycarbamide (also known as 
hydroxyurea), has a FDA license for the prevention of the com-
plications of SCD in adults and is associated with improvements 
in morbidity in the adult and pediatric sickle populations.
Hydroxycarbamide – mechanism 
of action
Hydroxycarbamide has been used for decades in many 
hematological disorders, in particular the myeloprolif-
erative disorders as a myelosuppressive agent. The first 
investigations into hydroxycarbamide as an agent that could 
potentially alter the production of fetal hemoglobin (HbF) 
was in anemic baboons,5,6 and it was first shown to raise 
levels of HbF in patients with SCD in 1985.7
Hydroxycarbamide belongs to a class of compounds 
called hydroxamic acids, which can bind metals. It inhibits 
ribonucleotide reductase by binding to two iron molecules 
on the reductase and inactivating a critical tyrosyl radical.8 
This accounts for its cytotoxic effect which is beneficial in 
many ways; it targets rapidly dividing cells, which in red 
cells tend to be those with a high level of HbS, and favors 
the production of red cells with a high HbF, as these tend to 
arise from red cells that divide less rapidly.
Another potential mechanism of action is the production 
of NO caused by the metabolism of hydroxycarbamide. 
Hydroxycarbamide activates guanylate cyclase, an enzyme 
containing heme, via a NO-dependent mechanism, which 
results in the production of HbF, as shown in vitro. The 
mechanism by which hydroxycarbamide generates NO is 
thought to be related to the NO/guanosine 3,5-cyclic mono-
phosphate (cGMP) pathway in erythroid progenitor cells.9 
The production of NO may also compensate for the loss of 
endogenous NO due to intravascular hemolysis.
Hydroxycarbamide has additional effects including 
a reduction in the numbers of white cells and platelets, 
potentially reducing their roles in vascular injury10 and also 
improves red cell hydration and decreases red cell adhesive-
ness to the endothelium.11,12
Role of hydroxycarbamide 
in prevention of acute painful 
crises and acute chest crises
Systematic reviews have looked at all randomized or 
quasi-randomized controlled trials comparing the use of 
oral hydroxycarbamide with placebo, standard therapy 
or other interventions for the treatment of  patients with 
SCD.13,14 Only 2 out of 7 studies15,16 were suitable for inclu-
sion in these reviews and they are described in detail below. 
One further study is ongoing.17 These reviews concluded that 
hydroxycarbamide appeared effective in severely affected 
adults with HbSS over a 2-year period; however, further 
studies are required to elucidate its role in other patient groups. 
In addition all individuals should be counseled prior to com-
mencing therapy relating to the known and potential risks.
Adult trials
Multicenter Study of Hydroxyurea (MSH)15
This was the first phase III double-blind, randomized controlled 
trial to look at the efficacy of hydroxycarbamide in reducing the 
frequency of  painful sickle crises. Two hundred and ninety-
nine adults with HbSS and a history of  3 or more crises a 
year were included and were randomly assigned to receive 
hydroxycarbamide (n = 152) or placebo (n = 147). Hydroxy-
carbamide was initiated at 15 mg/kg/day and increased every 
12 weeks by 5 mg/kg/day until the maximum tolerated dose 
(MTD) was reached. If marrow depression occurred, it was 
stopped until blood counts recovered and restarted at a dose 
2.5 mg/kg lower than the previous dose, starting a new 
12-week cycle. The patients were seen every 2 weeks and 
blood samples taken. A painful crisis was defined as a visit 
to a medical facility lasting more than 4 hours and requiring 
parenteral or oral narcotics. In addition patients filled 
out daily pain diaries, reviewed at each clinic visit.
There was a median rate of 2.5 crises per year in the 
hydroxycarbamide group, compared to 4.5 in the placebo 
group, which represented a 44% difference (P  0.001). 
When crises severe enough to warrant hospitalization were 
compared, the median annual rates were 1.0 in the hydroxy-
carbamide group and 2.4 in the placebo group (P  0.001). 
The incidence of chest syndrome also differed significantly 
with 25 patients developing acute chest syndrome (ACS) 
in the hydroxycarbamide group vs 51 in the placebo group 
(P  0.001). Both the frequency of blood transfusions 
(48 vs 73, P = 0.001) and number of red cell units transfused 
(336 vs 586, P = 0.004) were decreased in the group receiving 
hydroxycarbamide. There was no significant difference in the 
incidence of death, stroke and hepatic sequestration between 
the two groups.
The trial was stopped early, after 21 months of follow-up 
because of the beneficial results observed. Hb, mean cell 
volume (MCV), HbF and proportion of HbF cells were 
higher in the hydroxycarbamide group than the placebo Therapeutics and Clinical Risk Management 2009:5 747
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group at the time of study closure, and white blood cell 
count (WBC), platelets and reticulocyte counts were lower. 
They found the beneficial effects of hydroxycarbamide do 
not become manifest for several months, differences between 
the two groups in terms of MCV and HbF percent becoming 
apparent from 8 weeks. No deaths owing to treatment were 
described in the trial and no patients developed neoplastic dis-
orders. Treatment was permanently stopped in 14 patients in 
the hydroxycarbamide group for medical reasons and 6 in the 
placebo group. Treatment ceased temporarily in almost all of 
the patients treated with hydroxycarbamide because of mar-
row depression; blood counts recovered within approximately 
2 weeks. Hydroxycarbamide was associated with a raised 
hemoglobin in 11 patients, and despite it exceeding 12 g/dL, 
there were no adverse events.
This was an important study which demonstrated the 
clinical benefit of hydroxycarbamide in patients with severe 
homozygous SCD, which significantly reduced the median 
annual rate of painful crises and the incidence of ACS. It left 
further questions to be answered about optimal dose, further 
application, any benefit to prevent long-term organ damage, 
and long-term safety and tolerability data.
The MSH subsequently published 9-year follow-up 
observational data18 which estimated that there was a 40% 
reduction in overall mortality in the patients who had taken 
hydroxycarbamide. Complete data for 233 out of the original 
299 patients were obtained for the full 9 years, and during 
the follow-up study they were able to continue, stop or start 
hydroxycarbamide and were seen yearly from 1996 to 2001. 
Data were included from the beginning of the original MSH 
trial, which showed that 96 patients (31%) never received 
hydroxycarbamide, 48 (16%) received hydroxycarbamide for 
less than 1 year and 156 (52%) received hydroxycarbamide 
for 1 or more years. From the initial patient cohort, 25% (75) 
died during the trial or follow-up, 28 of the deaths being due 
to pulmonary complications. When the deaths were analyzed 
in terms of original randomized patient subgroups, there were 
no differences between the hydroxycarbamide and placebo 
arms, but this did not take into account the patients’ treat-
ment after the original randomized phase was completed. 
There was a difference in cumulative mortality between 
the 2 subgroups, although this was not statistically signifi-
cant (P = 0.35). Patients with reticulocyte counts less than 
250,000/mm3 and hemoglobin levels 9 g/dL had increased 
mortality (P = 0.002). Cumulative mortality at 9 years was 
28% when HbF levels were 0.5 g/dL or higher (P = 0.03). 
Individuals who had ACS during the trial had 32% mortality 
compared with 18% of individuals without ACS (P = 0.02). 
Patients with 3 or more painful episodes per year during 
the trial had 27% mortality compared with 17% of patients 
with less frequent episodes (P = 0.04). There were 3 cases 
of cancer, 1 case of in situ cervical cancer who had received 
63 months of hydroxycarbamide, 1 of breast carcinoma after 
47 months of hydroxycarbamide and 1 patient died of endo-
metrial carcinoma after 9 years of hydroxycarbamide.
Analyzing mortality in 3-month intervals according to 
hydroxycarbamide usage in the interval, death rates were 
reduced 40% during the 3-month intervals when patients 
were taking hydroxycarbamide (P = 0.04). Overall, the 
follow-up trial showed that adult patients taking hydroxy-
carbamide for frequent painful sickle episodes appear to have 
reduced mortality after 9 years of follow-up, and estimated 
this to be in the order of 40% overall reduction. Survival 
was related to HbF levels and frequency of vaso-occlusive 
events. These results must be interpreted with care as this 
is an observational study in which patients could choose 
whether or not they took the hydroxycarbamide.
Pediatric trials
Belgian study16
This randomized single blind placebo crossover trial of 
hydroxycarbamide, looked at 25 children and young adults 
with a median age of 9 years (range 2 to 22 years). They were 
randomized between placebo and hydroxycarbamide at a dose 
of 20 mg/kg/day for 2 weeks and the dose was increased to 
25 mg/kg/day if there was no increase in HbF. After 6 months 
they were switched to the other treatment. Three patients on 
the placebo and 16 on the hydroxycarbamide had no hospital-
izations during the 6 months of treatment, and there were no 
clinically relevant toxicities, implying that hydroxycarbamide 
decreased the incidence of painful crises in children as well 
as in adults.
Belgian Registry data19,20
Data from the Belgian Registry were initially published in 
200120 and updated in 2004.19 One hundred and twenty-seven 
patients with SCD were enrolled into the registry between 
1993 and 2002 and started on hydroxycarbamide; 99 for 2 or 
more vaso-occlusive crisis (VOC), 21 for an ACS, 7 for stroke, 
1 for transient ischemic attack (TIA), and 18 for abnormal 
trans-cranial dopplers (TCDs) only. One hundred and nineteen 
patients had HbSS, 4 HbSβ0 thalassemia, 3 HbSC and 1 HbSD. 
The median age at entry was 6 years (8 months to 19 years) 
and mean follow up was 47 months (1 to 8 years).
Hydroxycarbamide dosing was started at 20 mg/kg/day 
and escalated in increments of 5 mg/kg if felt appropriate by Therapeutics and Clinical Risk Management 2009:5 748
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the treating physician. The mean number of hospitalizations 
and duration of  hospital admissions dropped significantly 
during the 8 years of  hydroxycarbamide treatment (P  0.05). 
Ninety-two out of 109 (85%) patients treated with hydroxy-
carbamide for conventional clinical criteria were free of 
major events requiring hospitalization at 1 year. At 7 and 
8 years after initiation of treatment 6/24 (25%) and 5/14 
(36%) patients respectively, remained so.
Thirty-two patients with HbSS were monitored for 
6 years to assess the long term effects of hydroxycarbamide 
therapy. The median age at entry was 6 years (range 8 months 
to 19 years). Hospitalizations, acute painful crisis and 
ACS were more frequently observed during the fourth to 
sixth year of treatment than during the first 3 years. During 
the 6 years of hydroxycarbamide treatment 8/32 (25%) 
patients remained free from any SCD-related event requiring 
hospitalization. No strokes or TIA occurred in the 31 patients 
without a previous history of neurological events. There was 
1 recurrent stroke in an 8-year-old girl, 6 years after the initial 
event. The hydroxycarbamide dose was reduced over time 
with no effect on the hematological indices.
In the registry, 14 patients were less than 2 years old at 
the time of enrolment and of these 10 had a minimum follow-
up of 2 years hydroxycarbamide therapy. Their clinical 
events and hospitalizations were similar to those in older 
age groups over the same time period, the hospitalization 
durations being longer in the younger group.
HUG-KiDS study21
This was a phase I–II pediatric hydroxycarbamide trial used 
to determine if hydroxycarbamide would have a detrimental 
effect on the growth of school-aged children with HbSS.19 
This prospective observational trial enrolled 68 children 
and adolescents who had an age range of 5 to 16 years and 
included 28 female and 40 male patients. Patients were 
eligible if they had severe SCD with 3 or more painful 
events in 1 year or 3 or more episodes of ACS in the 2 years 
before trial entry and hydroxycarbamide was escalated to 
MTD. In addition they needed a minimum of 6 documented 
height and weight measurements recorded for at least 2 years 
preceding entry. They had serial height, weight and Tanner 
stage measurements during the study. Comparison data 
were obtained from the data from the Co-operative Study of 
Sickle Cell Disease (CSSCD), and 3 groups were compared: 
pretreatment HUG-KIDS, on-treatment HUG-KIDS and the 
CSSCD group. In girls, there were no significant differences 
in height or weight among the pre-treatment, on-treatment 
and CSSCD groups. Compared with the CSSCD groups, 
HUG-KIDS boys were heavier from 9 years of age (although 
not statistically significant) and pre-treatment HUG-KIDS 
boys were taller from 7 years of age (P  0.05). The Tanner 
stage transitions took place at appropriate ages. This study 
showed that treatment with hydroxycarbamide had no 
adverse effect on height or weight gain or pubertal develop-
ment in school-aged children with SCD.
Hydroxyurea Safety and Organ Toxicity 
trial (HUSOFT)
The original HUSOFT trial22 investigated the short term 
feasibility of hydroxyurea administration, toxicities, hema-
tologic effects and effect on spleen function in infants with 
SCD. This was a prospective, multicenter, open-label, 
single arm, pilot study. In the 2-year initial study, 28 infants 
with HbSS or HbSβ0 thalassemia, all unselected for disease 
severity between 6 and 28 months (median 15 months), 
were prospectively treated with hydroxycarbamide. This 
was given orally once a day at the fixed dose of 20 mg/kg 
as a liquid formulation.
Twenty-one infants completed 2 years of  hydroxycarbamide 
treatment. Hydroxycarbamide was well tolerated, produced 
mild toxicities, predominantly transient neutropenia, which 
was associated with a presumed viral infection in 70%. None 
had an associated invasive viral infection. Persistent or recur-
rent neutropenia required a decrease in dose in 3 patients. 
Anemia and thrombocytopenia were rare and no significant 
hepatic or renal toxicity was observed. Two patients had 
accidental overdoses of hydroxycarbamide, which resulted 
in a mild transient neutropenia in both. No adverse effects 
on growth were observed compared with untreated controls. 
There was maintenance of relatively stable elevated hemo-
globin and HbF levels, showing a clear response to hydroxy-
carbamide therapy. The study also suggested a possible 
beneficial effect on preservation of splenic function, but the 
numbers were too low for statistical significance.
The HUSOFT extension study followed on from this pilot 
study.23 This reported on the long-term efficacy and toxicity 
of hydroxycarbamide in infants. All 21 infants complet-
ing the original 2-year pilot study were offered continued 
liquid hydroxycarbamide therapy, and their dose was esca-
lated by 5 mg/kg every 6 months to a maximum dose of 
30 mg/kg/day. Of the 21 patients enrolled, 1 was removed 
because of non-compliance and 1 patient did not tolerate the 
dose increase, because of neutropenia. This patient required 
a permanent dose reduction to 27.5 mg/kg/day. Seventeen 
completed an additional 4 years, and 11 were treated for a 
total of 6 years. Removal from the study before 6 years was Therapeutics and Clinical Risk Management 2009:5 749
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due to non-compliance (in 4), parents’ request (4) recurrent 
ACS (1) and death from pneumococcal sepsis (1).
Increased and sustained values of Hb, MCV, HbF 
and F cells were observed during the extension trial. All 
patients who tolerated the dose escalation responded to 
hydroxycarbamide by raising the percentage of HbF. Levels 
of WBC, platelet count and reticulocyte levels were lower 
than those expected in untreated children and were lower at 
year 6 than year 3, possibly because of dose escalation. The 
treated patients had significantly fewer ACS events than 
untreated SCD patients; however there was no difference 
in the incidence of pain. This was attributed to the method 
of data collection as in this trial pain was recorded monthly 
whereas in some other trials, eg, the CSSCD study, pain 
frequency was recorded annually retrospectively.
Hydroxycarbamide was generally well tolerated, with 
8% cases of neutropenia compared to 10% in the pilot study 
above. Growth was not impaired among these children treated 
with hydroxycarbamide compared to standard growth curves. 
There was improved growth in some children, especially 
boys, a finding which has previously been demonstrated in 
boys21 and school-age children.24 A trend towards a delay in 
functional asplenia was observed and recovery of splenic 
function in was seen in 2 cases. There was no decrease in 
the rate of silent infarcts after 4 years of hydroxycarbamide 
therapy (21%), compared to the prevalence reported in 
untreated SCD children.
In conclusion, the extension study supported the findings of 
the initial pilot study described above that hydroxycarbamide 
is effective in young children, with little acute toxicity. In addi-
tion it showed the use of oral liquid formulation of hydroxy-
carbamide at a dose of 30 mg/kg/day is feasible, results in 
sustained hematological efficacy with relatively limited adverse 
events, decreases the ACS rate, and may improve growth.
Monitoring and dosing 
of hydroxycarbamide
Hydroxycarbamide has only recently been licensed for 
use in SCD in the UK, and the majority of UK patients 
are currently being prescribed the unlicensed formulation. 
In view of this, and the lack of long-term follow up data 
for hydroxycarbamide, it is vital that full informed consent 
is taken from patients who are commenced on hydroxy-
carbamide therapy and the use of a patient information 
sheet is advised. Hydroxycarbamide therapy is usually 
commenced at a starting dose of 15 mg/kg (rounded to the 
nearest 500 mg), as in the MSH study15 and the full blood 
count should be checked 2 weeks after initiation and after 
each dose increase. Once stable the full blood count should be 
checked every 6 to 8 weeks. If the patient is still symptomatic, 
then dose escalation should take place every 4 weeks until 
the blood count falls. At this point the hydroxycarbamide 
should be stopped until the full blood count has recovered 
and restarted at 2.5 mg/kg or 500 mg lower. This is the MTD. 
Liver function tests and urea and electrolytes should be 
checked every 8 weeks. HbF levels should also be checked 
regularly as this gives a good indication of response as does 
an increase in MCV . There are no studies looking at optimal 
timing of dose escalation and blood monitoring but UK expert 
opinion would support the above strategy.25
Hydroxycarbamide is renally excreted so dosage should 
be adjusted in patients with evidence of renal impairment, and 
a starting dose of 7.5 mg/kg should be given in patients with 
a glomerular filtration rate of less than 60 mL/minute.26
Maximum tolerated dose 
or minimum effective dose?
The majority of trials using hydroxycarbamide, including 
MSH, have commenced treatment at 15 mg/kg or 20 mg/kg 
and escalated treatment to the MTD or a maximum dose of 
30 mg/kg. It is not clear on current evidence whether it is 
necessary to dose escalate in this way, or whether patients 
should be treated with the minimum effective dose. Although 
the patients enrolled in the MSH study were intended to dose 
escalate to the MTD, many did not, only 33% of patients 
receiving the MTD by 6 months, and 53% at the time of 
study closure, suggesting that hydroxycarbamide is effective 
at doses lower than the MTD. Hydroxycarbamide therapy at 
the MTD has been shown to be well tolerated and has sus-
tained hematologic efficacy over several years of therapy.27 
In this trial hydroxycarbamide was initiated in 122 patients 
with severe SCD (106 HbSS, 7 HbSC, and HbS/β thalasse-
mia and 2 HbS/OArab) at a median age of 11.1 years (range 
0.5 to 19.7 years). Hydroxycarbamide was escalated to 
the MTD, with an average dose of 25.4 ± 5.4 mg/kg/day. 
The average duration of  treatment was 45 ± 24 months. Of  the 
122 patients, 21 received doses higher than 30 mg/kg/day 
(median 31.1 mg, range 30.1 to 36.1 mg/kg/day). It was 
discontinued in 15 children with poor compliance.
There were significant increases for all of the 122 patients 
in hemoglobin level, MCV , and HbF level. When analyzed 
according to genotype, the increase in hemoglobin concen-
tration was significant in all but the 8 patients with HbSC or 
HS/β+. Hydroxycarbamide led to a decrease in the rate of 
hemolysis, as shown by significant decreases in reticulocyte 
count and bilirubin levels. In addition, there were significant Therapeutics and Clinical Risk Management 2009:5 750
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decreases in WBC and platelet counts. Mild transient 
neutropenia occurred in 5% of  patients, but there was no hepatic 
or renal toxicity. There were no adverse effects on growth 
while on therapy, and many children had improved growth.
HbF induction was sustained for up to 8 years reaching 
levels of up to 20% which is the level suggested to provide 
clinical benefit.28 This was achieved without adverse effects 
on growth or increased numbers of DNA mutations as mea-
sured by the quantitative VDJ assay to look for acquired 
somatic mutations. No child on hydroxycarbamide in this 
study acquired myelodysplasia, leukemia or any other 
malignancy. These data showed that escalating the dose of 
hydroxycarbamide to the MTD in children could achieve the 
maximum and sustained beneficial hematologic effects on 
percentage HbF and WBC count but they did not show that a 
decrease in clinical severity paralleled the dose increases.
In adults, it has been shown that it is not always necessary 
to reach the MTD to produce good clinical effects.29 There is 
no current evidence to suggest that either MTD or minimum 
effective dosing regimes are safer or more efficacious and 
there are no long-term safety data beyond 8 years in children 
and 9 years in adults.
Adverse effects of hydroxycarbamide
The most common short-term side effect of hydroxy-
carbamide is myelosuppression, which requires careful 
monitoring with regular blood tests.
There is no established evidence of  malignancy caused 
by the use of hydroxycarbamide in SCD, but there have 
been a small number of cases of leukemia and lymphoma 
reported.15,30 This needs to be discussed with the patient and bal-
anced against the improvement in symptoms and mortality.
Animal studies have shown hydroxycarbamide to be 
embryotoxic/teratogenic,31 causing a number of birth defects. 
There have been 58 pregnancies reported in 57 women exposed 
to hydroxycarbamide during pregnancy which include one case 
of a fetal death and reduced growth and several minor malfor-
mations.32 The advice given currently to both male and female 
patients is not to conceive while on hydroxycarbamide and for 
3 months after cessation. Clinicians should ensure that their 
patients are aware of the recommendation to use contraception 
whilst on hydroxycarbamide. If a woman becomes pregnant 
while on hydroxycarbamide she should stop it immediately and 
should not recommence until breast feeding has stopped.
There are limited data on male fertility after ceasing 
hydroxycarbamide, and there is some evidence that fertility does 
not return to normal in all patients, even several months after 
cessation. Males’ sperm counts have been well described to be 
affected during therapy with hydroxycarbamide, predominantly 
in animal studies but also in a number of case studies,32 one study 
showing up to 40% of men had decreased sperm counts while 
on hydroxycarbamide.33 There are several case reports show-
ing a long-term effect of hydroxycarbamide on sperm counts, 
including a case of a sickle patient who became azoospermic 
after 7 months’ treatment with hydroxycarbamide who still 
had significantly reduced sperm count and sperm motility at 
1 year after cessation of treatment.34 A retrospective review of 
4 patients on hydroxycarbamide, 3 with sickle cell and 1 with 
myeloproliferative disease (MPD), showed variable effects 
on spermatogenesis. Unfortunately no pre-hydroxycarbamide 
data were available. The MPD patient was azoospermic while 
on hydroxycarbamide, and regained a normal sperm count, 
but with many abnormal forms and motility 3 months after 
cessation. Once hydroxycarbamide was restarted he again 
became azoospermic. A second patient had a normal count 
throughout treatment but reduced motility, although sperm 
count fell once treatment was ceased. The 3rd and 4th patients 
did not have data both on and off hydroxycarbamide.35
A further study has looked at the effects of hydroxy-
carbamide on sperm parameters, in 4 patients with sequen-
tial data, on and off hydroxycarbamide therapy.33 Of these, 
one became azoospermic, which persisted 4 years after 
cessation. Two others developed reduced sperm counts 
on hydroxycarbamide, which did not recover 3 to 5 years 
after stopping treatment. One patient’s sperm count was not 
affected during treatment, but there were concerns about the 
patient’s compliance.
The data from the above observational studies, although 
in small numbers, raise the question for the need to provide 
analysis and possible sperm banking for males starting 
hydroxycarbamide. The authors would recommend that sperm 
analyses and banking are offered to all men about to com-
mence hydroxycarbamide therapy, and that semen analysis 
is performed annually during therapy and when therapy is 
stopped. Ideally this should be done as part of a clinical trial.
Other side effects include hyperpigmentation of nails, 
nausea and vomiting, skin rash, alopecia and diarrhea. There 
was no evidence of an increased incidence of leg ulcers in 
the MSH study, despite the association of  hydroxycarbamide 
therapy and leg ulcers in myeloproliferative disease.36
UK guidelines – current indications 
for hydroxycarbamide
In the UK, there are recently published standards for the 
clinical care of adults and children with SCD which outline 
the indications for the use of hydroxycarbamide.37,38Therapeutics and Clinical Risk Management 2009:5 751
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These are peer-reviewed documents based on literature 
review and expert opinion. In adults37 hydroxycarbamide therapy 
is recommended for patients with moderate to severe SCD 
who have had 3 painful crises per year over the past 2 years 
requiring hospital admission, or have recurrent crises in the com-
munity which are severe enough to interfere with their activities 
of daily living, or who have had 2 or more acute chest syndromes, 
or 1 severe acute chest syndrome requiring ventilation.
Further possible indications, based on observational 
studies or anecdotal reports, include the following: Patients 
who have had a previous stroke, but are no longer willing 
or able to continue a transfusion program; patients with 
excessive hemolysis causing anemia; patients with repeated 
gallstone formation; or patients with anemia owing to renal 
disease, especially if they are not willing or able to have blood 
transfusion, pulmonary hypertension and priapism.
The pediatric guidelines38 recommend that hydroxy-
carbamide should be considered in patients who have recurrent 
episodes of acute pain (more than 3 admissions in the previous 
12 months, or are very symptomatic in the community) or who 
have had 2 or more episodes of acute sickle chest syndrome, 
or 1 acute chest syndrome requiring ventilation. They also 
state that the decision to start hydroxycarbamide should be 
made by the specialist center, although the local hospital 
will have a role in monitoring blood counts and side effects. 
The specialist center should have a written protocol which is 
shared with the local hospital. This should include informa-
tion about dose regimen, frequency of blood test monitoring, 
management of myelosuppression and contraindications for 
use of hydroxycarbamide. In addition the patient and/or their 
parents should be given a patient information sheet and the 
use of hydroxycarbamide should be discussed with them on 
at least 2 separate occasions. Current knowledge about side 
effects, including cytopenias and the possible risk of leukemia 
or other malignancies, should be discussed. This discussion 
should be documented in the patient’s notes.
The guidelines also state that there are still some areas 
which need clarification. These are the optimal dose; impact 
on long-term organ function; and risk of malignancy. For these 
reasons, they recommend that its use should be monitored 
with collection of data about long-term outcomes.
Emerging indications 
for hydroxycarbamide
Use of hydroxycarbamide to prevent stroke
Transcranial doppler (TCD) ultrasound is now recommended 
as a routine screening test for children with SCD from 
2 to 16 years of age, to identify patients at highest risk for 
primary stroke.39,40 There are emerging data that hydroxy-
carbamide may have a beneficial effect in primary or second-
ary prevention of  stroke in children but its role relative to that 
of  blood transfusion has not been defined by prospective trials. 
Until more data are available, blood transfusion is the modality 
of choice in treatment and prevention of stroke in SCD.
Primary prevention
The Belgian Registry data included a subgroup of 18 patients 
who were treated with hydroxycarbamide because they were 
at risk of stroke on the basis of an abnormal TCD. They 
did not meet the conventional criteria for commencing 
hydroxycarbamide. Eleven of these 18 patients were prospec-
tively followed by TCD, and 2 had velocities that returned to 
normal/conditional on hydroxycarbamide. In addition 8 patients 
at risk of secondary stroke were treated with hydroxycarbamide 
and followed for a median of 6 years. At trial entry only 5 of 
the 8 were still receiving chronic transfusion. Recurrent stroke 
occurred in 1 patient during the 6 years of follow-up. Thirty-four 
patients from the entire Belgian Registry (of 127 patients) 
were considered to be at risk of primary stroke on the basis of 
abnormal TCD, and only 1/34 presented with a cerebrovascular 
accident during an evaluation of 96 patient years. Evidence of 
silent infarction or neuropsychological change was not exam-
ined in this population.19
A prospective phase II trial has also looked at the effi-
cacy of hydroxycarbamide in primary prevention.41 TCD 
velocities were examined in 59 children who were initiat-
ing hydroxycarbamide therapy because of clinical severity. 
Thirty-seven out of the 59 had increased flow velocities 
(140 cm/second) at enrolment. The TCD velocities were 
then measured at MTD and at 1 year later. At the MTD, 
significant decreases were observed in the right and left 
middle cerebral artery velocities (P  0.001). The magnitude 
of TCD velocity decline was significantly correlated with 
the maximal baseline TCD value. At hydroxycarbamide 
MTD, 14/15 children with conditional baseline TCD values 
improved, while the TCD reduction of 5/6 patients with 
abnormal TCD velocities whose families refused transfusions 
decreased to 200 cm/second. These TCD changes were 
sustained at follow-up. A further prospective single-center trial 
has been reported which followed up 14 infants for 80 weeks 
or more. This group had a median age of 35 months (range 
21 to 53 months) and was treated with the MTD of hydroxy-
carbamide. Three patients had a conditional TCD at trial entry 
and these all reverted to the normal range by the end of the trial. 
No new MRI or MRA lesions were seen during the trial.42Therapeutics and Clinical Risk Management 2009:5 752
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Secondary prevention
In 16 patients with SCD and previous stroke, transfusion 
therapy was prospectively discontinued and hydroxy-
carbamide was initiated. At the time of reporting the 
patients had been off transfusion for a median of 22 months 
(3 to 52 range). Their average hemoglobin was 9.4 ± 1.3 d/dL 
and 14 patients underwent phlebotomy. Three patients 
(19%) had neurological events considered recurrent stroke, 
each 3 to 4 months after discontinuing transfusions, but 
before maximal hydroxycarbamide effects. These data sug-
gested that some patients may be able to discontinue chronic 
transfusions and use hydroxycarbamide therapy to prevent 
stroke recurrence.43
A further study44 looked at hydroxycarbamide as an 
alternative to transfusion in 5 children with SCD who had 
had a stroke, 3 after the first episode and 2 after the second 
CVA. Four had had an infarctive stroke, and 1 a TIA. None 
of the 5 patients had recurrence during 2 to 112 months of 
observation.
Phase iii Stroke With Transfusions 
Changing to Hydroxyurea  
(SWiTCH) trial
A phase III trial46 is currently underway including 
approximately 130 children (5.0 to 18.9 years of age with 
65 subjects per treatment arm) with SCD who have had 
symptomatic cerebral infarctions and have been treated 
with red cell transfusions for at least 18 months. After 
completing baseline screening studies, half the participants 
will be switched to a therapeutic program of hydroxyurea 
and phlebotomy. Half of the participants will remain on 
transfusion and chelation. The composite primary endpoint 
is to compare two modalities of treatment for the prevention 
of secondary stroke and management of iron overload. 
Hopefully this will provide some clear guidance as to the 
definitive role of hydroxycarbamide in the prevention of 
secondary stroke.
Conclusions from current evidence are that blood 
transfusion should be the treatment of choice for primary 
or secondary stroke prevention, but that hydroxycarbamide 
should be considered in patients who refuse or are unable 
to receive blood transfusion therapy. Further information 
will be obtained from the SWiTCH trial.
Effects on splenic function
There is emerging evidence, although not at all conclusive, 
that hydroxycarbamide may positively affect splenic func-
tion in children. The HUSOFT study suggested a possible 
delay in the progression toward functional asplenia cor-
roborated in the HUSOFT extension study.23 After 4 years 
of treatment with hydroxycarbamide there was a lower 
proportion of asplenic patients on hydroxycarbamide treat-
ment (43% vs the expected 94%), suggesting that hydroxy-
carbamide may be able to prevent the loss of splenic function. 
It does however raise the possibility of a prolonged risk of 
acute splenic sequestration in these patients which will need 
further investigation.
Additionally, a more recent retrospective review looked at 
splenic function at baseline and on treatment with hydroxy-
carbamide in 43 children.46 After a median of 2.6 years (range 
0.2 to 8.6 years) of hydroxycarbamide at the MTD, 6 patients 
(14%) completely recovered splenic function and 2 (5%) had 
preserved splenic function. These 8 children had a greater 
hemoglobin concentration on hydroxycarbamide therapy than 
Table 1 Current UK indications for use of hydroxycarbamide in adult and pediatric sickle cell disease
Indications in adults33 Indications in children34
Absolute indications  
(grade A evidence)
Possible indications  
(based on observational studies 
or anecdotal reports)
Absolute indications  
(grade A evidence)
3 painful crises per year over the past 
2 years requiring hospital admission
Previous stroke, but are no longer 
willing or able to continue a 
transfusion program
Recurrent episodes of acute pain 
(3 admissions in the previous 
12 months, or are very symptomatic 
in the community)
Recurrent crises in the community 
which are severe enough to interfere 
with their activities of daily living
excessive hemolysis causing 
anemia or repeated gallstone 
formation
2 acute chest syndromes
Anemia due to renal disease
Pulmonary hypertension
Priapism
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those without splenic function (9.1 vs 8.6 g/dL, P = 0.01). 
Although retrospective, the data suggest that hydroxy-
carbamide at MTD possibly preserves spleen and can even 
result in recovery of splenic function. In addition they suggest 
higher final hemoglobin concentration during therapy is a sig-
nificant laboratory predictor of improved splenic function.
Use in renal impairment
A prospective single center trial has been reported which 
followed up 14 infants for 80 weeks or more. This group 
had a median age of 35 months (range 21 to 53 months) 
and was treated with the MTD of hydroxycarbamide. DTPA 
glomerular filtration rate (GFR) was measured at trial entry and 
exit. Five children had a raised GFR of over 150 mL/minute 
at trial entry, implying hyperfiltration and early renal damage. 
At trial entry the GFR had not risen as expected in the group 
of patients with a normal GFR at trial entry and the GFR in 
two patients with a raised GFR at trial entry had returned 
to normal.42 A retrospective analysis of hydroxyurea in 
combination with enalapril in children with SCD and sickle 
nephropathy47 has looked at the laboratory effects of the 
two drugs. Enalapril reduced the urinary protein excretion 
and normalized serum albumin. There was a suggestion 
that the addition of hydroxycarbamide further normalized 
the urine/protein creatinine ratio. This would merit further 
investigation.
Future areas for research
Role of hydroxycarbamide 
in different genotypes
The majority of trials listed above have been limited to 
patients with HbSS, or included small numbers of patients 
with other genotypes, including HbSC, HbS thalassemia, and 
HbSD.15,20,23 A decrease in frequency and severity of painful 
crises has been shown in studies of non-HbSS patients and 
this trial confirms subanalysis of other trials that patients 
with HbSC may tolerate lower doses of hydroxycarbamide 
before reaching the MTD.27,48 These have only involved small 
patient numbers and would merit further investigation.
Other indications
A single-center study has reported on an improvement in 
chronic hypoxia in 3 pediatric patients when treated with 
hydroxycarbamide. This would merit further investigation.49
Pharmacotherapy combination
There are many other agents currently being investigated, 
both individually and in combination with hydroxycarbamide. 
They work in a variety of ways, some inducing HbF, others 
by varying other mechanisms, such as inhibition of normal 
membrane ion exchange channels, inhibition of endothe-
lial or cell surface adhesion molecules, and as nitric oxide 
modulators.50
For example, in a recent report of the National Institutes 
of Health (NIH) experience,51 13 adult patients were given 
a combination of hydroxycarbamide and erythropoietin. 
These patients were either hydroxycarbamide intolerant 
due to reticulocytopenia, or had renal insufficiency. 
Erythropoetin plays an important role in dose escalation 
of hydroxycarbamide, while preventing erythroid toxicity, 
especially in the setting of renal impairment. An ongoing 
NIH phase I clinical trial is investigating the combination of 
these agents in adult patients with SCD and renal dysfunc-
tion and/or evidence of pulmonary hypertension (http://
www.clinicaltrials.gov#NCT00270478). This will further 
clarify the role of erythropoietin and hydroxycarbamide 
combination therapy.
Summary
The efficacy of hydroxycarbamide in defined populations 
with SCD, both adult and pediatric, has been established 
since its first use in 1985. With its use has come a decrease 
in morbidity supplemented by increasing standards of care.
Unfortunately it is not a drug without side effects or 
risk and requires detailed pre-treatment counseling and 
careful monitoring of blood counts, which can limit com-
pliance to therapy. Ongoing investigation into new agents 
may provide some further treatments; however at present 
hydroxycarbamide is the only effective treatment for patients 
with severe to moderate SCD. Its efficacy at reducing the 
frequency of vaso-occlusive crisis and acute chest crisis is 
well established. Its precise role and effects in certain popula-
tions such as stroke prevention and organ preservation is still 
being established, and some questions remain.
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